Metformin is a common first-line drug for type-2 diabetes that is now being studied for anti-aging. Metformin is a medication that has been used by millions of people for decades and is considered extremely safe when taken according to instructions. Its anti-aging effects appear to influence metabolic pathways that aid in turning off bad genes and flipping on longevity genes.
This, of course, positively influencing the aging process. In fact, it can help switch on key longevity genes that may improve healthspan and longevity in humans for decades or more. Metformin is currently being studied throughout the world in major research institutions for this very reason. This combined with a healthier lifestyle can add years or decades to your life. For example, the risk of death from these diseases accelerates up to one-thousand times between the ages of thirty-five and eighty-five years in humans.
For this reason, the U. They are investigating the development of new interventions to improve and maintain health into old age. Anti-Aging and Wellness has been around for many years. Those who practiced anti-aging medicine used to be demonized and ridiculed, but now the tides are turning. We believe the new Anti-Aging community is on the march, and the out-dated consensus-based medical establishment is on the run. Metformin is an FDA approved first-line drug for the treatment of type 2 diabetes, has known beneficial effects on glucose metabolism.
It has been used for decades by millions of type 2 diabetics and is considered safe. Because of this, metformin has been used by the anti-aging community for years to help control glucose metabolism. It is now being studied in the United States for aging since it may influence fundamental aging factors that underlie multiple age-related conditions.
Soon when the FDA approved anti-aging studies are completed on metformin, we believe we will see that metformin will restore the gene expression profile of older adults with impaired glucose tolerance to that of a younger age person.
One small study in California showed this with nine adults. After taking metformin, human growth hormone, and D H E A for one year, the group showed an average of two and one-half years of age reversal at the cellular level.
Go to antiagemedical. Metformin is only beneficial for type-2 diabetics. Lactic acidosis can occur for patients who overdose on metformin. This is why a doctor must work closely with patients.
The possibility of lactic acidosis is most risky among type 1 diabetics who do not produce insulin. Always work closely with a knowledgeable healthcare professional knowledgeable in optimal metformin protocols for blood glucose regulation.
That is, increase our ability to live independently and free from debilitating disease states. For more than years, modern allopathic medicine has been targeting specific diseases independent of one another. Each disease was often treated by a specialist in that disease e. Since our leading diseases are strongly associated with aging, scientists are now looking at using medications like metformin to influence aging pathways.
If metformin studies succeed, hundreds of thousands of lives may be saved each year from age-related chronic diseases. Metformin should not be the only intervention, we also promote lifestyle coaching on diet and nutrition. Each year the CDC reports overdeaths annually due to heart disease,deaths annually due to cancers, For a detailed breakdown see infographic below. For years the anti-aging movement has targeted certain effects of aging through hormone replacement and dietary manipulation.Metformin, a drug taken by many with diabetes, may have much greater potential beyond controlling blood sugar, some experts say.
Metformin may influence fundamental aging factors that underlie many age-related conditions, including cancer, heart disease and Alzheimer's, says Nir Barzilai, MD, director of the Institute for Aging Research at Albert Einstein College of Medicine, the Bronx.
Barzilai says. And accumulating data suggests that ''it interferes with the biology of aging. Aging, he says, is a primary risk factor for not only diabetes but also most of our big killers, such as Alzheimer's, heart disease and cancer.
In animal and human studies, metformin has shown promise in slowing the aging process and halting diseases. To study the potential of metformin further, Dr. In that study, they gave some participants metformin, at 1, milligrams a day, and others placebo. Barzilai knows he has critics of his approach.
He brushed them off, saying the people who don't see the value of the research ''don't understand the biology of aging and that it can be changed. He doesn't see the research as testing an anti-aging drug. However, age is a risk factor for many disabling conditions, he says. He calls that extending the ''health span. Research has found that metformin reduces harmful oxidative stress and inflammation, among other benefits, he says. He is familiar with the clinical trial protocol of Dr.
Other drugs look more promising, he says. However, an important goal of the study is to set precedent, he says, to show that an older person's gene profile can be reset. Researchers have been looking at the potential of metformin for about 15 years, Dr.
Kennedy says, and research includes positive results in both animal and human studies. In one often-quoted study, diabetic patients taking metformin lived longer than those not on it, including those without diabetes. Researchers looked at more than 78, people with diabetes on metformin, more than 12, with diabetes on drugs known as sulfonylureas and more than 90, people who did not have diabetes. The researchers found that those with type 2 diabetes on metformin lived longer than those in the non-diabetic comparison group and those on the other drug.
The researchers wrote that the finding implies metformin may confer benefit in those without diabetes. The finding may be partially explained by those with diabetes seeing their doctor more, and having conditions caught earlier, Dr. Kennedy says. Even so, he says, "I still think it's an important study.
Barzilai estimates the new study will start in a year or two. The study will last five or six years. If results bear out, approval of the drug for aging could be secured soon after that, he says.
Asked if metformin is being used off-label now to prevent the age-related diseases, he says: "I hope not. Because we haven't done the study. We need it to succeed the way we want it to succeed'' before recommending it, he says. Email Print Discuss. Written by Kathleen Doheny. You May Also Like:.Can Niacinamide and Metformin Reverse Aging? An Anti-aging Experiment of One by Edward Omron MD
Depression in Type 1 and Type 2 Diabetes. Follicular Thyroid Cancer.New York physician is treating patients with an anti-aging drug regimen. This article details which medications the doctor prescribes and why he prescribes them. An earlier version had incorrectly listed the practice as being in Chicago. I apologize for the error. Anti-aging drugs are still in the process of being fully vetted. The FDA does not approve aging as a treatable disease.
Statins, aspirin and blood pressure medications are already approved by the FDA to treat heart disease. The drugs metformin and rapamycin are not yet approved to treat aging and are currently in clinical trials to test their life-extension powers.
Alan S. Green, M. According to his website, starting in JanuaryDr. Green began taking rapamycin personally, as well. In a bid to ward off the ravages of aging, Dr. Green takes the medication along with other drugs already available at the local drugstore.
In addition to intermittent rapamycinDr. The powerful immune suppressant is already used in transplant patients to prevent them from rejecting donor organs. Scientists believe the drug blocks the key aging pathway shared by all animals. The drug has extended the lifespan of every animal tested so far, from yeast to mice to monkeys. In a well-publicized experiment, rapamycin increased the average lifespan of middle-aged mice by about a third.
Green started taking 6mg of rapamycin, once a week, in a therapeutic practice called intermittent rapamycin dosing. For comparison organ transplant patients typically take 1 mg every 12 hours of a form of rapamycin called everolimus. While Dr. Intermittent rapamycin dosing has been shown to reduce side effects in humans and to extend the lifespan of mice. According to Dr. There is growing evidence to support the life-extending effects of once a week dosing with rapamycin.
A related report describes the evidence behind low-dose intermittent rapamycin therapy. The New York anti-aging physician prescribes statins in his anti-aging cocktail.
One of the side effects of rapamycin is that it induces high cholesterol, a condition known as hyperlipidemia. According to the doctor, the statins used are used to counteract the side effect of rapamycin. Physicians use statins to treat high cholesterol. Also known as HMG-CoA reductase inhibitors, researchers have found that statins reduce cardiovascular disease and mortality in high-risk patients.
The evidence is strong that statins effectively treat heart disease in the early stages, in what is known as secondary prevention. Furthermore, researchers believe that statins have lifespan-extending effects that extend beyond their cholesterol-lowering abilities. Physicians use the drug metformin to treat type 2 diabetes.
Researchers have found that the drug has remarkable anti-aging powers in this group. Green uses metformin in the anti-aging cocktail for two reasons.Ariel Poler is a veteran angel investor who spends his days traveling around the Bay Area to meet with entrepreneurs. Now in his early fifties, he also thinks a lot more about his own health, so he makes an effort to keep his stress levels low by eating well and taking regular kite-surfing trips.
But he also takes a tiny, white pill called metformin, which is prescribed to millions of people with diabetes to help control high blood sugar. Poler does not have diabetes, but he takes it for a different reason. He hopes that it will help keep him healthier for longer.
Unlike some in Silicon Valleywho are increasingly investing in wonder drugs and starting companies to crack the code on aging, Poler isn't planning to live forever. But he does believe that his metformin use, coupled with his commitment to nutritious food and exercise, will help delay the onset of serious health issues. He's not alone. Metformin is undergoing a bit of a renaissance in Silicon Valley tech circles -- among people who do not have diabetes.
CNBC interviewed a dozen executives and investors working in the tech industry who take the drug as a hedge against aging. Some were willing to speak publicly about it, while others preferred to remain anonymous as they did not want their employers to find out.
Bolstering their case, there are also some high-profile supporters in the medical field, including the renowned aging researcher Nir Barzilai.
Metformin is not a new innovation. The drug, which is available in generic form for about 5 cents a pill, has been around for decades. But in recent years, researchers have studied the long-term effects and found that diabetics who took it for years wound up experiencing unintended health benefits, including a reduced cancer risk compared to the general population. Further studies of the drug in mice showed evidence of an improved life span. The drug is thought to mimic some of the positive effects of calorie restriction by lessening the amount of sugar the body produces and absorbs.
Calorie restriction is a huge challenge for people to maintain, as it involves eating a lot less over a long period of time, but some studies have shown that it can help to extend the human life span. The side effects associated with prolonged metformin use include diarrhea, slow blood sugar, and abdominal pain. The most serious risk is that excessive acid accumulates in the body, causing a condition known as lactic acidosis.
Poler hasn't experienced any of these side effects, so he intends to continue taking it for the long-term. All of them agree that metformin's effects have been under-studied, in part because there isn't much of a financial incentive for the pharmaceutical industry to research the impact of an extremely cheap, generic drug. That could explain why doctors don't routinely recommend it to people without diabetes, and why metformin hasn't made it into the mainstream.
Medical experts said they have mixed feelings about whether people without diabetes should take the drug, in light of this lack of research. Burrell said he wouldn't "block" a patient from taking it, but he would also educate them about the lack of human data. Animal trials can be useful, but humans and mice often react differently to medications so it's not enough to prove safety and efficacy. Sign up for free newsletters and get more CNBC delivered to your inbox.
Get this delivered to your inbox, and more info about our products and services. All Rights Reserved.
U.S. Doc Prescribing Anti-Aging Cocktail To Seniors
Data also provided by. Skip Navigation. Markets Pre-Markets U. Key Points. People in tech are increasingly taking metformin, a commonly-prescribed diabetes drug, in a bid to stay healthier for longer. It's fairly safe as millions of people have taken the drug, but there are side effects.
Doctors have mixed feelings about the trend, given the lack of clinical evidence. VIDEO Others who take metformin maintain that it's already benefiting them.Study record managers: refer to the Data Element Definitions if submitting registration or results information. Aging in humans is a well-established primary risk factor for many disabling diseases and conditions, among them diabetes, cardiovascular disease, Alzheimer's disease and cancer.
In fact, the risk of death from these causes is dramatically accelerated fold between the ages of 35 and 85 years. For this reason, there is a need for the development of new interventions to improve and maintain health into old age - to improve "healthspan". Several mechanisms have been shown to delay the aging process, resulting in improved healthspan in animal models, including mammals. At Einstein, the investigators have been working to discover pathways associated with exceptional longevity.
The investigators propose the study of drugs already in common clinical use and FDA approved for a possible alternative purpose -healthy aging. The investigators goal is to identify additional mechanisms involved in aging, the delay of aging and the prevention of age-related diseases.
In this proposal, the investigators explore the possibility of a commonly used drug, metformin, to reverse relevant aspects of the physiology and biology of aging. It is the first-line drug of choice for prevention and treatment of type 2 diabetes T2DM. The effect of metformin on aging has been extensively studied, and has been associated with longevity in many rodent models. Metformin also extends the lifespan of nematodes, suggesting an evolutionarily conserved mechanism.
A recent high impact study demonstrated that metformin reduces oxidative stress and inflammation and extends both lifespan and health span in a mouse model. If indeed metformin is an "anti-aging" drug, its administration should be associated with less age-related disease in general, rather than the decreased incidence of a single age-related disease.
This notion led investigators to further study whether anti-aging effects can be demonstrated in the type 2 diabetes population. This has been suggested in other studies and meta-analyses and remains an active area of research.
In addition, numerous epidemiologic studies have shown an association of metformin use with a decreased risk of cancer, as well as decreased cancer mortality. There is also evidence from studies performed both in-vitro and in-vivo of metformin's role in attenuating tumorigenesis. The mechanisms proposed relate to its effects on reducing insulin levels, improved insulin action, decreased IGF-1 signaling central to mammalian longevityas well as activation of AMP-kinase.
In fact, metformin's potential protective effect against cancer has been gaining much attention, with over ongoing studies registered on the Clinical Trials.
To characterize pathways associated with increased lifespan and healthspan, the investigators plan to compile a repository of muscle and adipose biopsy samples obtained from young healthy subjects and older adults before and after treatment with potential anti-aging drugs. RNA-Seq analysis will be used to identify a unique biological "fingerprint" for aging in these tissues by comparing changes in gene expression in older adults post-drug therapy to the profiles of young healthy subjects.
The investigators believe that if metformin changes the biology of aging in tissues to a younger profile, it supports the notion that this drug may have more widespread use - as an "anti-aging" drug. The investigators will test this by identifying increases in gene expression in muscle and adipose tissue with RNA Sequencing RNA-Seq in metformin and in placebo. A higher Matsuda index indicates better insulin sensitivity. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies. The investigators chose these inclusion criteria in order to study subjects who have evidence of impaired glucose regulation, but are not yet diabetic. Hide glossary Glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information. Search for terms x. COVID is an emerging, rapidly evolving situation.
Save this study.Remember me This is not recommended for shared computers. Sign in anonymously Don't add me to the active users list. Posted 28 April - PM. Sinclair told The Washington Post that he was taking mg of resveratrol a day when he was 45 in and still had a biological age of 58 according to what he recently revealed in an interview.
Metabolic aging, fasting and metformin
Before he began taking mg of NMN, he said his blood work showed that his biological age was that of a 58 year old but after the NMN, it had reversed to Mechanisms of Mild Cellular Stress Response.
Maybe Dr. The daily mail is sort of like the National Inquirer. Still there might sometimes be a grain of truth in some of their articles. Whatever virtues NMN may have in regards to resveratrol, I have my doubts about this article. I believe the blood test mentioned in the daily mail was this one reported in Nature.
Quoting from the paper: "We found smoking, high BMI and consumption of sugar-sweetened beverages to increase the predicted chronological age by 2—6 years, while consumption of fatty fish, drinking moderate amounts of coffee and exercising reduced the predicted age by approximately the same amount.
I do note that Sinclair's measures are self-reported, perhaps inaccurately. Both of which are discussed extensively elsewhere in Longecity's forums. Posted 29 April - PM. There is much more than just a "grain of truth" in that Daily Mail article, which includes several quotes and explanations by Sinclair. We don't know which aging test Sinclair used but "soulprogrammer" posted on the NR Curated thread that it may have been the free site Aging AI 2.
After taking NR for quite a while dose not mentioneda 62 year old entered his data and got 28 years while a 59 year old got 39 years - but pre NR results not used. Sinclair, 47, said his pre NMN biological age was estimated to be 58 and after taking NMN for 3 months had an estimate of 32 years old.
Is Sinclair lying about his estimated biological age as you suggest? It is possible, but I doubt it. I forgot to add that it is possible Sinclair stopped taking his mg of resveratrol and any other supplements for a while in order to get an NMN only "before" reading.
If so, he should have said that in the interview. I believe Sinclair said he is going to do clinical trials on NMN. Can't make very much money on NR, so expect to see a drug similar to the rapalogs for rapamycin where you need a RX and they can charge plenty.
Take a look a study 1 at this site and see if you can make sense of the chart of increase in NMN by different dosages of NR.
Thanks for linking the video. Maybe my impression was wrong. Yet if NR proves to be helpful based on the results of the person Chromadex study coming out in a few weeks, why would people take NMN that costs maybe twice as much by the time it goes to market in to ? NR researcher Charles Brenner has said resveartrol is worthless and is skeptical that pterostilbine does much, but I doubt he is right about either.
They believe the two together are synergistic. I'm not aware of anyone who has got the results that his father got from taking the NMN.Summary: Report on metformin and anti-aging medicine. Used for decades to treat type 2 diabetesmetformin is showing promise as an anti-aging drug.
Researchers are looking into whether metformin holds the key to living longer — and the latest research has been favorable. What we know today as metformin, has a long history. Doctors have been prescribing it as an herbal remedy for centuries. French physician Jean Sterne isolated the active compound from the French lilac in the s. Today, we know that compound as metformin. Metformin was introduced as a medication in France in and was approved by the FDA for treating type 2 diabetes inand in other countries decades earlier.
The inexpensive generic is also used off-label to treat other conditions like gestational diabetes, prediabetesand polycystic ovarian disease. A growing body of evidence shows that the drug prevents cancer, heart disease, and type 2 diabetes. Using metformin as an anti-aging drug makes sense since it helps the body use insulin properly, lowering blood sugar.
Metformin decreases glucose production in the liver, decreases intestinal absorption of glucose, and improves insulin sensitivity. Because metformin effectively lowers both blood sugar and insulin levels, it also reduces the risk of many other chronic degenerative diseases. Metformin also promotes weight loss. The evidence on metformin and anti-aging has come from observational studies. Nor are they convinced by the observational studies that metformin can slow down aging in the general population.
The goal of TAME is to prove that both metformin and anti-aging drugs are topics worth further investment. Nir Barzilai, MD is the leading spokesperson for metformin and anti-aging science in general. Barzilai knows a thing or two about aging, as he is currently director of the Institute for Aging Research at the Albert Einstein College of Medicine. Barzilai is an expert on the genetics of aging, metformin and anti-aging medicine.
Wired reporter Sam Apple caught up with Dr. Barzilai and asked him about metformin and anti-aging in July of this year. After talking to Dr. Barzilai and other anti-aging researchers, the correspondent summarized the powers of metformin:. When they did get cancer, they tended to outlive diabetics with cancer who were taking other medications.
Nir Barzilai, MD, has received acclaim for his work on metformin and anti-aging in general. Early in his career, Dr. Barzilai conducted a series of studies on centenarians, people who live to an unusually old age. The doctor discovered that centenarians died from the same chronic diseases as everyone else, but they developed them the at ends of their lives.
In other words, they somehow managed to slow the aging process and compress the diseases of aging into their last years. Barzilai drew blood samples from hundreds of centenarians and studied their genetic code to find out what made them live longer than most.